{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T03:40:07Z","timestamp":1749440407010,"version":"3.41.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10620-025-08909-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T20:11:50Z","timestamp":1740082310000},"page":"1547-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States"],"prefix":"10.1007","volume":"70","author":[{"given":"Kevin","family":"Pak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Sachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"8909_CR1","unstructured":"WHO. IARC Monographs on the Identification of Carcinogenic Hazards to Humans WHO. https:\/\/monographs.iarc.who.int\/list-of-classifications. Accessed 2024"},{"key":"8909_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40364-024-00611-y","volume":"12","author":"M Zhang","year":"2024","unstructured":"Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12:84. https:\/\/doi.org\/10.1186\/s40364-024-00611-y.","journal-title":"Biomark Res."},{"key":"8909_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/v15040997","author":"YS Lim","year":"2023","unstructured":"Lim YS, Kim WR, Dieterich D et al. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15040997.","journal-title":"Viruses."},{"key":"8909_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12:33\u201334. https:\/\/doi.org\/10.1002\/cld.728.","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"8909_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, Electronic address EEE, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol."},{"key":"8909_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4.","journal-title":"Hepatol Int."},{"key":"8909_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13914","author":"LY Mak","year":"2024","unstructured":"Mak LY, Yee LJ, Wong RJ, Ramers CB, Frenette C, Hsu YC. Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase. J Viral Hepat. 2024. https:\/\/doi.org\/10.1111\/jvh.13914.","journal-title":"J Viral Hepat."},{"key":"8909_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jvh.13511","volume":"28","author":"K Yao","year":"2021","unstructured":"Yao K, Liu J, Wang J et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28:1025\u20131033. https:\/\/doi.org\/10.1111\/jvh.13511.","journal-title":"J Viral Hepat."},{"key":"8909_CR9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.cgh.2021.01.019","volume":"20","author":"DQ Huang","year":"2022","unstructured":"Huang DQ, Li X, Le MH et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol. 2022;20:1803-1812 e5. https:\/\/doi.org\/10.1016\/j.cgh.2021.01.019.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8909_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","volume":"78","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Tran A, Yeh ML et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78:1558\u20131568. https:\/\/doi.org\/10.1097\/HEP.0000000000000459.","journal-title":"Hepatology."},{"key":"8909_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/sjg.sjg_279_23","volume":"30","author":"YS Lim","year":"2024","unstructured":"Lim YS. Gray zone of hepatitis B virus infection. Saudi J Gastroenterol. 2024;30:76\u201382. https:\/\/doi.org\/10.4103\/sjg.sjg_279_23.","journal-title":"Saudi J Gastroenterol."},{"key":"8909_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/hep.21724","volume":"46","author":"CK Hui","year":"2007","unstructured":"Hui CK, Leung N, Yuen ST et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46:395\u2013401. https:\/\/doi.org\/10.1002\/hep.21724.","journal-title":"Hepatology."},{"key":"8909_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1186\/s12879-024-09617-1","volume":"24","author":"M Duan","year":"2024","unstructured":"Duan M, Xiao H, Shi M et al. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT. BMC Infect Dis. 2024;24:723. https:\/\/doi.org\/10.1186\/s12879-024-09617-1.","journal-title":"BMC Infect Dis."},{"key":"8909_CR14","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1007\/s10620-021-07009-y","volume":"67","author":"MH Lin","year":"2022","unstructured":"Lin MH, Li HQ, Zhu L et al. Liver fibrosis in the natural course of chronic hepatitis B viral infection: a systematic review with meta-analysis. Dig Dis Sci. 2022;67:2608\u20132626. https:\/\/doi.org\/10.1007\/s10620-021-07009-y.","journal-title":"Dig Dis Sci."},{"key":"8909_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373. https:\/\/doi.org\/10.1001\/jama.295.1.65.","journal-title":"JAMA."},{"key":"8909_CR16","unstructured":"HHS. Hepatitis B Basic Information. https:\/\/www.hhs.gov\/hepatitis\/learn-about-viral-hepatitis\/hepatitis-b-basics\/index.html#:~:text=for%20possible%20treatment.-,How%20Many%20People%20Have%20Hepatitis%20B?,to%20the%20World%20Health%20Organization%20. Accessed 14 Sep 2024"},{"key":"8909_CR17","unstructured":"CDC. Clinical Overview of Hepatitis B. CDC. https:\/\/www.cdc.gov\/hepatitis-b\/hcp\/clinical-overview\/index.html#:~:text=Long%2Dterm%20effects&text=Acute%20hepatitis%20B%20is%20a%20short%2Dterm%20illness%20that%20is,with%20no%20lasting%20liver%20damage. Accessed 13 Oct 2024"},{"key":"8909_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/jvh.13873","volume":"30","author":"QY Gan","year":"2023","unstructured":"Gan QY, Wang JX, Qian F et al. Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2023;30:803\u2013809. https:\/\/doi.org\/10.1111\/jvh.13873.","journal-title":"J Viral Hepat."},{"key":"8909_CR19","doi-asserted-by":"publisher","first-page":"e0011","DOI":"10.1097\/HC9.0000000000000011","volume":"7","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim SU, Seo YS, Ahn SH, Rim CH. Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis. Hepatol Commun. 2023;7:e0011. https:\/\/doi.org\/10.1097\/HC9.0000000000000011.","journal-title":"Hepatol Commun."},{"key":"8909_CR20","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-50. https:\/\/doi.org\/10.1053\/j.gastro.2004.09.014.","journal-title":"Gastroenterology."},{"key":"8909_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3350\/cmh.2021.0019","volume":"27","author":"TC Yip","year":"2021","unstructured":"Yip TC, Wong GL, Wong VW. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Clin Mol Hepatol. 2021;27:273\u2013277. https:\/\/doi.org\/10.3350\/cmh.2021.0019.","journal-title":"Clin Mol Hepatol."},{"key":"8909_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","volume":"67","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lim YS, Han S et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945\u2013952. https:\/\/doi.org\/10.1136\/gutjnl-2017-314904.","journal-title":"Gut."},{"key":"8909_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3350\/cmh.2020.0216","volume":"27","author":"MY Jeon","year":"2021","unstructured":"Jeon MY, Kim BK, Lee JS et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clin Mol Hepatol. 2021;27:295\u2013304. https:\/\/doi.org\/10.3350\/cmh.2020.0216.","journal-title":"Clin Mol Hepatol."},{"key":"8909_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/apt.15741","volume":"52","author":"HA Lee","year":"2020","unstructured":"Lee HA, Lee HW, Kim IH et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther. 2020;52:196\u2013204. https:\/\/doi.org\/10.1111\/apt.15741.","journal-title":"Aliment Pharmacol Ther."},{"key":"8909_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53776-0","author":"HW Lee","year":"2019","unstructured":"Lee HW, Kim SU, Baatarkhuu O et al. Comparison between chronic hepatitis B patients with untreated immunetolerant phase vs those with virological response by antivirals. Sci Rep UK. 2019. https:\/\/doi.org\/10.1038\/s41598-019-53776-0.","journal-title":"Sci Rep UK."},{"key":"8909_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cgh.2014.07.019","volume":"13","author":"S Yapali","year":"2015","unstructured":"Yapali S, Talaat N, Fontana RJ, Oberhelman K, Lok AS. Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. Clin Gastroenterol Hepatol. 2015;13:193-201 e1. https:\/\/doi.org\/10.1016\/j.cgh.2014.07.019.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8909_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","volume":"11","author":"CJ Chen","year":"2007","unstructured":"Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis. 2007;11:797\u2013816. https:\/\/doi.org\/10.1016\/j.cld.2007.08.005.","journal-title":"Clin Liver Dis."},{"key":"8909_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/apt.15725","volume":"51","author":"GA Kim","year":"2020","unstructured":"Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51:1169\u20131179. https:\/\/doi.org\/10.1111\/apt.15725.","journal-title":"Aliment Pharmacol Ther."},{"key":"8909_CR29","unstructured":"WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. https:\/\/www.who.int\/publications\/i\/item\/9789240090903. Accessed 14 Sep 2024"},{"key":"8909_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154833","author":"WM Choi","year":"2022","unstructured":"Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI154833.","journal-title":"J Clin Invest."},{"key":"8909_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/HEP.0000000000000752","volume":"80","author":"WM Choi","year":"2024","unstructured":"Choi WM, Yip TC, Kim WR et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: a multinational cohort study of HBeAg-positive patients. Hepatology. 2024;80:428\u2013439. https:\/\/doi.org\/10.1097\/HEP.0000000000000752.","journal-title":"Hepatology."},{"key":"8909_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/gutjnl-2023-330225","volume":"73","author":"WM Choi","year":"2024","unstructured":"Choi WM, Kim GA, Choi J et al. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024;73:649\u2013658. https:\/\/doi.org\/10.1136\/gutjnl-2023-330225.","journal-title":"Gut."},{"key":"8909_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.031","author":"WM Choi","year":"2024","unstructured":"Choi WM, Yip TC, Wong GL et al. Baseline viral load and on-treatment hepatocellular carcinoma risk in chronic hepatitis B: a multinational cohort study. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.031.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8909_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.11.018","author":"J Che-To Lai","year":"2024","unstructured":"Che-To Lai J, Wong GLH, Tse YK, Hui VWK, Sze-Man Lai M, Chan HLY, Wong VWS, Yip TCF. Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.018.","journal-title":"J Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08909-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08909-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T02:59:01Z","timestamp":1749437941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08909-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["8909"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08909-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS is on the speaker bureau for Gilead Pharmaceuticals, AbbVie, Takeda, Salix, Ipsen, Madrigal, Mallinckrodt. He works as a consultant for Gilead, Ipsen, Cymabay, Madrigal, Mallinckrodt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}